Synapse - Naiyer Rizvi

Results (166)

Exon 20 mutations of the epidermal growth factor receptor (Egfr) in lung adenocarcinomas: Clinicopathologic factors and response to therapy

Meeting Abstract

Naidoo, J.; Sima, C. S.; Hellmann, M. D.; Arcila, M. E.; Rizvi, N. A.; Yu, H. A.
Journal of Thoracic Oncology (2014)

Fulltext@MSK | Save

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS

Journal Article

Christner, S. M.; Parise, R. A.; Levine, E. D.; Rizvi, N. A.; Gounder, M. M.; Beumer, J. H.
Journal of Pharmaceutical and Biomedical Analysis (2014)

Fulltext@MSK | Save

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)

Meeting Abstract

Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors

Meeting Abstract

Rizvi, N. A.; Infante, J. R.; Gibney, G. T.; Bertino, E. M.; Cooley, S. A.; Lekatis, K.; Wigginton, J. M.; Gutierrez, A. A.; Gupta, A. K.; Kim, S. Y.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)

Meeting Abstract

Rizvi, N. A.; Antonia, S. J.; Man Chow, L. Q.; Brahmer, J. R.; Juergens, R. A.; Borghaei, H.; Shepherd, F. A.; Laurie, S. A.; Gerber, D. E.; Wade Goldman, J.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial

Meeting Abstract

Heist, R. S.; Gandhi, L.; Shapiro, G.; Rizvi, N. A.; Burris, H. A.; Bendell, J. C.; Baselga, J.; Yerganian, S. B.; Hsu, K.; Ogden, J.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC)

Meeting Abstract

Gettinger, S. N.; Brahmer, J. R.; Rizvi, N. A.; Ready, N.; Chow, L. Q. M.; Antonia, S. J.; Buyse, M. E.; Jassem, J.; Finckenstein, F. G.; Crinò, L.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials

Meeting Abstract

Drilon, A. E. D.; Wang, L.; Hasanovic, A.; Joubert, P.; Kris, M. G.; Riely, G. J.; Ladanyi, M.; Rizvi, N. A.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC)